Merck projects $64.1B-$65.6B revenue in 2025 amid WINREVAIR growth and GARDASIL rebasing
Q4 2024 Management View Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted ...
Healio5d
Winrevair PAH trial stopped due to earlier ‘robust evidence’
Back to Healio The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence ...